Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatic disease in injection drug users.

Brent D Lemberg1, Thomas A Shaw-Stiffel

  • 1Department of Internal Medicine, Gastroenterology Unit-Hepatology Section of Strong Memorial Hospital, University of Rochester, 601 Elmwood Avenue, Box 646, Rochester, NY 14642, USA. Thomas_Shawstiffel@urmac.rochester.edu

Infectious Disease Clinics of North America
|October 10, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Henoch-Schönlein purpura.

Postgraduate medicine·2017
Same author

Diffuse desmoplastic metastatic breast cancer simulating cirrhosis with severe portal hypertension: a case of "pseudocirrhosis".

Digestive diseases and sciences·2007
Same author

Acute liver failure as an initial manifestation of an infiltrative hematolymphoid malignancy.

Digestive diseases and sciences·2006
Same author

Use of hepatitis B core antibody-positive donors in recipients without evidence of hepatitis B infection: a survey of current practice in the United States.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2003
Same author

Liver transplantation in mushroom poisoning.

Journal of clinical gastroenterology·2002
Same journal

Prevention and Control of Clostridioides difficile Infection for the Infectious Diseases Clinician.

Infectious disease clinics of North America·2026
Same journal

Infection Control Strategies to Prevent Emergence and Transmission of Resistant Gram-Negative Bacteria.

Infectious disease clinics of North America·2026
Same journal

Preventing the Spread of Tuberculosis in Health Care Settings.

Infectious disease clinics of North America·2026
Same journal

Threats to Success: Principles of Infection Prevention and Control in Health Care Settings, Part 2: Device and Pathogen Management.

Infectious disease clinics of North America·2026
Same journal

Ventilator-Associated Events: Surveillance and Prevention.

Infectious disease clinics of North America·2026
Same journal

Nosocomial Fungal Infections: Epidemiology, Control Strategies, and Prevention of Candida and Other Yeasts.

Infectious disease clinics of North America·2026
See all related articles

Viral hepatitis, including hepatitis B and C, significantly impacts injection drug users. Improved treatments are needed, with tailored protocols for this population to prevent severe liver disease and improve outcomes.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Public Health

Background:

  • Viral hepatitis, particularly hepatitis B and C, is highly prevalent among injection drug users (IDUs).
  • Hepatitis B affects 1.5 million and hepatitis C affects over 4 million individuals in the US, with many being IDUs.
  • Chronic hepatitis can lead to severe liver conditions like cirrhosis and hepatocellular carcinoma.

Purpose of the Study:

  • To highlight the critical need for specialized treatment protocols for viral hepatitis in injection drug users.
  • To address the challenges posed by lifestyle factors and compliance rates in IDUs.
  • To emphasize the importance of early intervention for preventing advanced liver disease in this demographic.

Main Methods:

  • Literature review on viral hepatitis prevalence in IDUs.

Related Experiment Videos

  • Analysis of current treatment limitations for IDUs.
  • Discussion of potential strategies for improved intervention and compliance.

    • Main Results:

    • Viral hepatitis is a major infectious disease concern for IDUs.
    • Existing hepatitis treatments lack specific adaptations for the IDU population.
    • Low compliance rates are a significant barrier to effective management in IDUs.

    Conclusions:

    • There is a pressing need for evidence-based, tailored treatment and management strategies for hepatitis B and C in injection drug users.
    • Early and consistent intervention is crucial to mitigate the risk of cirrhosis, liver cancer, and the need for transplantation.
    • Developing specific protocols can improve health outcomes for this vulnerable population.